Spark YG™ 570 anti-human CD309 (VEGFR2) Antibody, CD309, A16085I,BioLegend,374006

Host

Mouse

Reactivity

Human

Application

IHC-P -Quality tested

Platform ID

BAB173506086

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameSpark YG™ 570 anti-human CD309 (VEGFR2) Antibody, CD309, A16085I
Cat. No.374006
HostMouse
RRIDAB_2860956 (BioLegend Cat. No. 374005)AB_2860957 (BioLegend Cat. No. 374006)
IsotypeMouse IgG2b, κ
ReactivityHuman
ApplicationIHC-P -Quality tested
ClonalityMonoclonal
Clone NumberA16085I
Concentration0.5 mg/mL
TargetCD309
ImmunogenRecombinant Human VEGFR2-Fc Chimera
PurityThe antibody was purified by affinity chromatography and conjugated with Spark YG™ 570 under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
StorageThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light.Do not freeze.
Regulatory StatusResearch Use Only

Scientific Background

CD309, also known as VEGF-R2, KDR, and Flk-1 (mouse), is a type I transmembrane glycoprotein. It is a member of the CSF-1/PDGF receptor family of type III tyrosine kinase receptors. Human VEGF-R2 is mainly expressed by endothelial cells, embryonic tissues, and megakaryocytes. It plays an important role in the regulation of angiogenesis, vasculogenesis, and vascular permeability. The ligands of VEGF-R2 include VEGF-A, VEGF-C, and VEGF-D splice isoforms. Activation of VEGF-R2 with its ligands results in the receptor dimerization and autophosphorylation, stimulating endothelial cell proliferation and migration.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.